Loading institutional data...
Loading institutional data...
Held by 4,451 of 5,944 reporting institutions (100th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $270.22 today, the market must believe free cash flow compounds 15.4%/yr for a decade (off $19.3B normalized FCF).
The market's 15.4% is more optimistic than its 9-yr track record.
2-stage DCF · 2.41B shares · net debt $28.2B
mean 2.9% · volatility σ 8% · implied rate exceeded in 0/9 yrs
Central path = implied 15.4%/yr growth; shaded band = ±1σ (8%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 | FY2021 | FY2019 | FY2018 | FY2017 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94.19B 100.0% | $88.82B 100.0% | $85.16B 100.0% | $79.99B 100.0% | $78.74B 100.0% | $82.58B 100.0% | $82.06B 100.0% | $81.58B 100.0% | $76.45B 100.0% | $71.89B 100.0% |
| Cost of Revenue | $30.26B 32.1% | $27.47B 30.9% | $26.55B 31.2% | $24.60B 30.7% | $23.40B 29.7% | $28.43B 34.4% | $27.56B 33.6% | $27.09B 33.2% | $25.44B 33.3% | $21.79B 30.3% |
| Cost of Products | — | — | — | — | — | — | — | $27.09B 33.2% | $25.44B 33.3% | $21.79B 30.3% |
| Gross Profit | $63.94B 67.9% | $61.35B 69.1% | $58.61B 68.8% | $55.39B 69.3% | $55.34B 70.3% | $54.16B 65.6% | $54.50B 66.4% | $54.49B 66.8% | $51.01B 66.7% | $50.10B 69.7% |
| Research & Development | $109.0M 0.1% | $1.84B 2.1% | $483.0M 0.6% | $0 0.0% | $0 0.0% | — | — | — | — | — |
| Selling, General & Admin | $23.68B 25.1% | $22.87B 25.7% | $21.51B 25.3% | $20.25B 25.3% | $20.12B 25.5% | $22.08B 26.7% | $22.18B 27.0% | $22.54B 27.6% | $21.52B 28.1% | $20.07B 27.9% |
| Interest Expense | $971.0M 1.0% | $755.0M 0.9% | $772.0M 0.9% | $276.0M 0.3% | $183.0M 0.2% | $201.0M 0.2% | $318.0M 0.4% | $1.00B 1.2% | $934.0M 1.2% | $726.0M 1.0% |
| Interest & Investment Income | $1.06B 1.1% | $1.33B 1.5% | $1.26B 1.5% | $490.0M 0.6% | $53.0M 0.1% | $111.0M 0.1% | $357.0M 0.4% | $611.0M 0.7% | $385.0M 0.5% | $368.0M 0.5% |
| Other Income (Expense), net | $7.21B 7.7% | -$4.69B -5.3% | -$6.63B -7.8% | -$810.0M -1.0% | -$526.0M -0.7% | -$2.90B -3.5% | -$2.52B -3.1% | -$1.41B -1.7% | $42.0M 0.1% | -$210.0M -0.3% |
| Pretax Income | $32.58B 34.6% | $16.69B 18.8% | $15.06B 17.7% | $19.36B 24.2% | $19.18B 24.4% | $16.50B 20.0% | $17.33B 21.1% | $18.00B 22.1% | $17.67B 23.1% | $19.80B 27.5% |
| Income Tax Expense | $5.78B 6.1% | $2.62B 3.0% | $1.74B 2.0% | $2.99B 3.7% | $1.38B 1.7% | $1.78B 2.2% | $2.21B 2.7% | $2.70B 3.3% | $16.37B 21.4% | $3.26B 4.5% |
| Net Income | $26.80B 28.5% | $14.07B 15.8% | $35.15B 41.3% | $17.94B 22.4% | $20.88B 26.5% | $14.71B 17.8% | $15.12B 18.4% | $15.30B 18.8% | $1.30B 1.7% | $16.54B 23.0% |
| Per Share | ||||||||||
| EPS (Basic) | $11.13 | $5.84 | $13.88 | $6.83 | $7.93 | $5.59 | $5.72 | $5.70 | $0.48 | $6.04 |
| EPS (Diluted) | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 | $5.51 | $5.63 | $5.61 | $0.47 | $5.93 |
| Weighted Avg Shares (Basic) | 2.41B | 2.41B | 2.53B | 2.63B | 2.63B | 2.63B | 2.65B | 2.68B | 2.69B | 2.74B |
| Weighted Avg Shares (Diluted) | 2.43B | 2.43B | 2.56B | 2.66B | 2.67B | 2.67B | 2.68B | 2.73B | 2.75B | 2.79B |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash conversion lags reported earnings — watch accruals. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $6.0B buybacks = $6.0B returned on $19.7B FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Insufficient data. Current ROIC on all capital: 21%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $19.7B covers the $2.0B due within a year 9.9× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-28 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.” Effective rate ~2.0% on $47.9B of debt.
Cash of $19.7B fully covers short-term debt of $8.5B.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
Nothing notable to watch.
No material risks flagged.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Operating leverage needs meaningful revenue change.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2021 | FY2022 | FY2023 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 33.2 | 33.6 | 34.4 | 29.7 | 30.7 | 31.2 | 30.9 | 32.1 |
| Gross Profit | 66.8 | 66.4 | 65.6 | 70.3 | 69.3 | 68.8 | 69.1 | 67.9 |
| R&D | — | — | — | 0.0 | 0.0 | 0.6 | 2.1 | 0.1 |
| SG&A | 27.6 | 27.0 | 26.7 | 25.5 | 25.3 | 25.3 | 25.7 | 25.1 |
| Income Tax | 3.3 | 2.7 | 2.2 | 1.7 | 3.7 | 2.0 | 3.0 | 6.1 |
| Net Income | 18.8 | 18.4 | 17.8 | 26.5 | 22.4 | 41.3 | 15.8 | 28.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on JNJ: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
Peers = companies sharing JNJ's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position